This case illustrates the challenges in managing SLE with peripheral neuropathy and highlights the emerging role of telitacicept, a novel BLyS/APRIL dual inhibitor, as an effective and safer alternative. This evidence concerns the gene TNFSF13 and systemic lupus erythematosus.